Clinical trials: Cancer of the Prostate
Prostate Cancer
Impact of Catheter Size on Peri-Operative Pain After Robotic Assisted Laparoscopic Prostatectomy
This study is designed to assess the effect of catheter size on postoperative catheter pain, urinary continence, urinary flow rates, post void residuals, International Prostate Symptom Scores (IPSS), and Quality of Life (QoL)…
- Trial name
- NCT04098809
- Testing
- 16 French urinary catheter, 20 French urinary catheter
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Benaroya Research Institute
Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7
A Phase II Neoadjuvant Study of Apalutamide, Abiraterone Acetate, Prednisone, Degarelix and Indomethacin in Men With Localized Prostate Cancer Pre-prostatectomy
This phase II trial studies how well apalutamide, abiraterone acetate, prednisone, degarelix, and indomethacin work in treating patients with prostate cancer that has spread from where it started to nearby tissue or lymph nodes…
- Conditions
- Stage III Prostate Adenocarcinoma AJCC v7, Stage III Prostate Cancer AJCC v7, Stage IV Prostate Adenocarcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7
- Trial name
- NCT02849990
- Testing
- Abiraterone Acetate, Apalutamide, Degarelix
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Washington
Prostate Cancer
Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00786682
- Testing
- docetaxel, hydroxychloroquine
- Where
- 7 sites in United States
- Volunteers
- 11 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Prostate Cancer
Vaccine Therapy in Treating Patients With Non-Metastatic Prostate Cancer
RATIONALE: Vaccines made from tumor cells or dendritic cells may help the body build an effective immune response to kill tumor cells. It is not yet known which vaccine is more effective in treating patients with prostate cancer.
- Trial name
- NCT00814892
- Testing
- allogeneic tumor cell vaccine, therapeutic autologous dendritic cells
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Mayo Clinic
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
This phase I trial studies if positron emission tomography (PET) imaging using 11C-YJH08 can be useful for detecting certain cell receptor expression in tumor cells in patients with cancer that has spread to other parts of the…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04927663
- Testing
- Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Rahul Aggarwal
NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC)
A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Advanced Solid Tumors (MK-8628-006)
This is a study to determine the recommended dose of birabresib (MK-8628)(formerly known as OTX015) for further studies in participants with advanced nuclear protein in testis (NUT) midline carcinoma (NMC), triple negative breast…
- Conditions
- NUT Midline Carcinoma (NMC), Triple Negative Breast Cancer (TNBC), Non-small Cell Lung Cancer (NSCLC), Castration-resistant Prostate Cancer (CRPC)
- Trial name
- NCT02698176
- Testing
- Birabresib
- Volunteers
- 13 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
A Study of Immediate 9 Months Adjuvant Hormone Therapy With Triptorelin 11.25 mg Versus Active Surveillance After Radical Prostatectomy in High Risk Prostate Cancer Patients.
The purpose of this study is to assess the benefit of immediate hormonal treatment after Radical Prostatectomy in Chinese and Russian patients with high risk prostate cancer.
- Trial name
- PRIORITI (NCT01753297)
- Testing
- Triptorelin 11.25 mg
- Where
- 18 sites in China, Russia
- Volunteers
- 226 people
- Sponsor
- Ipsen
Prostatic Cancer
Quinacrine Treatment in Patients With Androgen-Independent Prostate Cancer
The purpose of this study is to determine whether quinacrine is effective in the treatment of Androgen-Independent Prostate Cancer.
- Trial name
- NCT00417274
- Testing
- Quinacrine
- Volunteers
- 31 people
- Sponsor
- Cleveland BioLabs
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
68Ga-PSMA-11 PET for the Diagnosis of Metastatic Castration Resistant Prostate Cancer
This phase II trial studies the use of 68Ga-PSMA-11 positron emission tomography (PET) in diagnosing patients with prostate cancer that continues to grow despite the surgical removal of the testes or medical intervention to block…
- Conditions
- Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8
- Trial name
- NCT04716725
- Testing
- 68Ga-PSMA-11, Positron Emission Tomography (PET)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Thomas Hope
Prostate Cancer
Safety Study of Autologous Dendritic Cells Injected Into the Prostate After Cryoablation for Advanced Prostate Cancer
The purpose of this study is to determine if the intra-tumoral injection of a subject's own dendritic cells after cryotherapy of the prostate is a safe and effective treatment for advanced prostate cancer.
- Trial name
- CRITICAL (NCT00753220)
- Testing
- VDC2008, Cyclophosphamide
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Bostwick Laboratories
Metastatic Prostate Cancer
Risedronate to Prevent Skeletal Related Events in Patients With Metastatic Prostate Cancer Commencing Hormonal Therapy
Risedronate is an orally administered pyridinyl bisphosphonate that is 36 times more potent than pamidronate and 72 times more potent than clodronate.
- Trial name
- NCT00216060
- Testing
- Risedronate
- Where
- 45 sites in United States, Canada
- Volunteers
- 63 people
- Sponsor
- Christopher Sweeney, MBBS
Prostate Carcinoma Metastatic to the Bone, Castration Resistant Prostate Cancer
A Positron Emission Tomography/Computed Tomography (PET/CT) Bone Imaging Study in Patients Receiving Enzalutamide for Castration-Resistant Prostate Cancer (CRPC)
The purpose of this study is to evaluate 18F-sodium fluoride positron-emission tomography / computed tomography (18F-NaF PET/CT) imaging as a method for determining treatment response in metastatic bone lesions in patients who…
- Trial name
- NCT02384382
- Testing
- Enzalutamide
- Where
- 5 sites in United States
- Volunteers
- 23 people
- Sponsor
- Pfizer
Pain, Metastatic Breast Cancer
Quell Opioid Reduction and Pain Relief in Patients With Cancer
To study effects the Quell device has on opioid consumption and pain relief in patients with cancer.
- Conditions
- Pain, Metastatic Breast Cancer, Prostate Cancer, Colorectal Cancer
- Trial name
- NCT02809846
- Testing
- Quell
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Scripps Translational Science Institute
Prostate Cancer
Fostering Shared Decision-making About Prostate Cancer Screening Among Clinicians and African American Men
This behavioral clinical trial assesses the efficacy of a educational intervention to increase shared decision making about prostate-specific antigen (PSA)-based screening for prostate cancer among African American males.
- Trial name
- NCT03869216
- Testing
- Educational Shared Decision-Making Intervention
- Where
- United States
- Volunteers
- 161 people, healthy volunteers welcome
- Sponsor
- Xavier University of Louisiana.
Prostate Cancer
ABT-751 in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as ABT-751, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00471718
- Testing
- ABT-751
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- Vanderbilt-Ingram Cancer Center
Metastatic Castration-resistant Prostate Cancer
Avelumab Plus 2nd-generation ADT in African American Subjects With mCRPC
This is a nonrandomized, open-label trial of avelumab in subjects with metastatic castration-resistant prostate cancer (mCRPC) experiencing PSA or radiographic progression while receiving 2nd generation ADT (abiraterone /…
- Trial name
- NCT03770455
- Testing
- Avelumab, 2nd generation ADT (abiraterone or enzalutamide)
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Jodi Layton, MD
Prostate Cancer
Phase II PAP Plus GM-CSF Versus GM-CSF Alone for Non-metastatic Prostate Cancer
The investigators are trying to find new methods to treat prostate cancer. The approach the investigators are taking is to try to enhance patients' own immune response against the cancer.
- Trial name
- NCT01341652
- Testing
- pTVG-HP, rhGM-CSF
- Where
- 3 sites in United States
- Volunteers
- 99 people
- Sponsor
- University of Wisconsin, Madison
Stage I Prostate Cancer, Stage IIA Prostate Cancer
Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer
This randomized phase II trial studies how well green tea extract works in treating patients with low-risk prostate cancer. Green tea extract contains ingredients that may prevent or slow the growth of certain cancers.
- Conditions
- Stage I Prostate Cancer, Stage IIA Prostate Cancer, Stage IIB Prostate Cancer
- Trial name
- NCT01928485
- Testing
- active surveillance, Sunphenon, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Sanjay Gupta PhD
Prostatic Neoplasms, Castration-Resistant
A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to: a) establish the recommended phase 2 dose (RP2D) and to evaluate the antitumor activity and safety of niraparib combination therapies (Combinations 1 and 2) and b) to determine the relative…
- Trial name
- QUEST (NCT03431350)
- Testing
- Niraparib 200 mg, Cetrelimab 240 mg, Cetrelimab 480 mg
- Where
- 50 sites in United States, Belgium and 5 more
- Volunteers
- 136 people
- Sponsor
- Janssen Research & Development, LLC
Prostate Cancer
To Evaluate Sipuleucel-T Manufactured With Different Concentrations of (PA2024) Antigen
This is a randomized, multicenter, single blind, Phase 2 trial of immunotherapy in men with metastatic androgen independent prostate cancer to evaluate sipuleucel-T manufactured with different concentrations of PA2024 antigen
- Trial name
- NCT00715078
- Testing
- sipuleucel-T
- Where
- 12 sites in United States
- Volunteers
- 122 people
- Sponsor
- Dendreon
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.